GNFTF - Conatus' Failure Was A Blow But The Most Important Study Is Yet To Come
Recently, Conatus Pharmaceuticals (CNAT) reported results from a phase 2b study known as ENCORE-PH. It noted that this study had failed to meet on the primary endpoint; however, there are still many shots on goal left. This is why I believe that this biotech has a chance to recover. For starters, final data from the ENCORE-PH study is going to be reported by mid-2019. In addition, the 1st half of 2019 has two other studies that are set to report results which are ENCORE-NF and ENCORE-LF.
Phase 2 ENCORE-PH
The phase 2b study